Skip to content

Quantitative Evaluation of the Breast's Morphological Variations During Radiotherapy: MorphoBreast3D

Quantitative Evaluation of the Breast's Morphological Variations During Radiotherapy: Monocentric Feasibility Study MorphoBreast3D

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03801850
Acronym
MB3D
Enrollment
60
Registered
2019-01-14
Start date
2018-02-22
Completion date
2020-05-07
Last updated
2020-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adjuvant Radiotherapy, Breast Cancer Female

Keywords

volume variation, deformation, repositioning, dosimetric quality, 3D scan

Brief summary

Quantitative evaluation of the breast's morphological variations during radiotherapy consisting in performing three-dimensional surface acquisitions of the breast in order to study its shape and volume. Evaluation of the dosimetric impact of these variations.

Interventions

DEVICE3D surface scan

measurement of inter fractional deformations by surface scanning

Sponsors

Centre Paul Strauss
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women * In situ or invasive breast carcinoma * Treated by conservative breast surgery * Pre-treatment with authorized chemotherapy * Eligible for conventional breast irradiation in 25 sessions of 2 Gy with or without irradiation of the tumor bed and lymph nodes area * Conventional 3D radiotherapy technique * Bra cup size from A to D included * Speaking and understanding french * Having given written consent * Patient with health insurance

Exclusion criteria

* Surgical treatment by mastectomy * No indication for breast radiotherapy * Local or diffuse inflammatory state of the breast at inclusion * History of epilepsy or anticonvulsive treatment for preventive or curative purposes * BMI\> 30kg / m2 * T4 stage tumor * Bilateral breast tumor * Use of a ventilatory control to treat the patient * Minor patient or major incompetent * Patient deprived of liberty * Patient under safeguard of justice

Design outcomes

Primary

MeasureTime frameDescription
Impact of breast morphology or volume changes during the breast irradiation on the total dose administeredChange of the dose delivered in the breast from the baseline treatment planification at the end of the treatment (at 5 weeks for in-situ carcinoma and at 6.5 weeks for invasive carcinoma)To analyse the effect of morphological changes in the breast during breast radiotherapy on the dose really administered in the remaining mammary gland after breast-conserving surgery compared to the dose initially planned.

Secondary

MeasureTime frameDescription
Preliminary quantitative assessment of breast deformations (mm) during breast radiotherapy following breast cancer conservative surgeryAt 1, 5, 12, 19, 26, 33 and 43 days from the start of the treatment (corresponding to the fraction number 1, 5, 10, 15, 20, 25, 33)
Breast deformation and volume measurements reproducibilitybefore treatment startEvaluation of the reproducibility of deformation and volume measurements between 2 consecutive surface scan acquisition. Reproducibility was calculated in accordance with International Organization of Standardisation (ISO 5725-2) and American Society for Testing and Material E177
Deviation between the breast volume calculated and the breast volume manually delineatedbefore treatment startEvaluation of the difference between the initial breast volume calculated by the software developed for the study and the delineated volume
Preliminary quantitative assessment of breast volume changes (mL) during breast radiotherapy following breast cancer conservative surgeryAt 1, 5, 12, 19, 26, 33 and 43 days from the start of the treatment (corresponding to the fraction number 1, 5, 10, 15, 20, 25, 33)
Correlation between textural data and radio-induced erythemaAt 1, 5, 12, 19, 26, 33 and 43 days from the start of the treatment (corresponding to the fraction number 1, 5, 10, 15, 20, 25, 33)
Potential dose distribution alteration despite no variation of the 95Recalculated or the D2Recalculatedat the end of each treatment (at 5 weeks for in-situ carcinoma and at 6.5 weeks for invasive carcinoma)
Required measurement time (surface scan)At 1, 5, 12, 19, 26, 33 and 43 days from the start of the treatment (corresponding to the fraction number 1, 5, 10, 15, 20, 25, 33)Mean time (in minutes) needed to perform a surface scan

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026